BC
EW icon

Bridgefront Capital’s Edwards Lifesciences EW Stock Holding History

Bridgefront Capital’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$365K Buy
+4,033
New +$338K 0.1% 332
2025
Q4 		– Sell
-10,085
Closed -$784K – 604
2025
Q3 		$784K Sell
10,085
-10,181
-50% -$795K 0.23% 136
2025
Q2 		$1.59M Buy
20,266
+9,286
+85% +$693K 0.42% 38
2025
Q1 		$796K Buy
+10,980
New +$786K 0.23% 129
2024
Q4 		– Sell
-11,458
Closed -$756K – 640
2024
Q3 		$756K Buy
+11,458
New +$832K 0.29% 90
2023
Q4 		– Sell
-16,572
Closed -$1.15M – 427
2023
Q3 		$1.15M Buy
+16,572
New +$1.33M 0.8% 9
2022
Q4 		– Sell
-10,949
Closed -$905K – 405
2022
Q3 		$905K Buy
+10,949
New +$1.05M 0.93% 7
2022
Q2 		– Sell
-2,815
Closed -$331K – 334
2022
Q1 		$331K Buy
+2,815
New +$316K 0.41% 83
2021
Q2 		– Sell
-5,455
Closed -$456K – 687
2021
Q1 		$456K Buy
5,455
+1,260
+30% +$107K 0.14% 265
2020
Q4 		$383K Buy
+4,195
New +$348K 0.13% 287

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Bridgefront Capital's EW Position: Q2 2026 in Review

Bridgefront Capital opened a new position in Edwards Lifesciences (EW) in Q2 2026: 4,033 shares worth $365K. The stake represents 0.1% of the portfolio and ranks #332 among its holdings. This is a return to the name: Bridgefront Capital previously reported a position in EW as recently as Q3 2025.

Bridgefront Capital first reported a position in EW in Q4 2020 and has held it in 10 quarters since. The position peaked at $1.59M in Q2 2025. 1,338 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Bridgefront Capital held 4,033 shares of Edwards Lifesciences worth $365K as of Q2 2026.
  • Edwards Lifesciences was a new Bridgefront Capital position in Q2 2026.
  • Edwards Lifesciences made up 0.1% of Bridgefront Capital's portfolio in Q2 2026, its #332 holding.
  • Bridgefront Capital first reported a position in Edwards Lifesciences in Q4 2020 and has held it in 10 quarters since.
  • Bridgefront Capital's Edwards Lifesciences position peaked at $1.59M in Q2 2025.
  • 1,338 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.